Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years Moderna Inc (NASDAQ: MRNA) Benzinga · Apr 28, 2022
Moderna applies for US clearance of COVID shot for young kids Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus. Tribune News Service · Apr 28, 2022
Analyzing Moderna Inc's Short Interest Moderna Inc's (NASDAQ:MRNA) short percent of float has fallen 6.25% since its last report. The company recently reported that it has 16.21 million shares sold short, which is 4.65% of all regular shares that are available for trading. Benzinga · Apr 26, 2022
Poland, Moderna Working Towards Increased Flexibility Of COVID-19 Vaccine Contracts: Reuters Poland can compromise with Moderna Inc (NASDAQ:MRNA) on increasing the flexibility of COVID-19 vaccine contracts, Reuters reported citing the health minister, striking an upbeat tone after initial talks with the company. Poland has said it will not take or pay for more doses of the COVID-19 vaccine under the European Union's supply contract. Reuters… Benzinga · Apr 25, 2022
What's Going On With Moderna Shares? Shares of vaccine companies, including Moderna Inc (NASDAQ: MRNA), are trading higher amid COVID-19 concerns due to rising cases in China. Benzinga · Apr 25, 2022
Moderna Says Dual Variant COVID-19 Booster With Beta is Better Effective Against Omicron Than Current Jab Moderna Inc (NASDAQ:MRNA) said a COVID-19 booster designed to target the Beta variant and the original coronavirus generated a better immune response against several virus variants, including Omicron. Moderna said the results were a good sign for the company's plans for future shots targeting two COVID-19 variants. The company said the bivalent… Benzinga · Apr 19, 2022
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses… Benzinga · Apr 18, 2022
Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19… Benzinga · Apr 14, 2022
Why Did Moderna Recall Thousands Of COVID-19 Vaccine Doses In Europe? Moderna Inc (NASDAQ:MRNA) recalled 764,900 doses of its COVID-19 vaccine made by its Spanish contract manufacturer Rovi after a foreign body contaminated a vial. No safety issues have been identified, Moderna said, about the lots distributed in Norway, Poland, Portugal, Spain, and Sweden in January. Japanese authorities last year suspended the use of… Benzinga · Apr 11, 2022
Moderna recalls thousands of COVID vaccine doses in Europe Moderna Inc said on Friday it was recalling 764,900 doses of its COVID-19 vaccine made by its contract manufacturer Rovi after a vial was found contaminated by a foreign body. Reuters · Apr 8, 2022
See Why COVAX, African Union Refuse To Buy More Moderna's COVID-19 Vaccine COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine despite the low immunization rate as developing nations struggle to allocate supplies. The African Union and Covax decided not to obtain more of the vaccine as developing nations struggle… Benzinga · Apr 5, 2022
Why Moderna Shares Are Trading Lower Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday following reports indicating that both the African Union and COVAX Consortium have declined to purchase the company's COVID-19 vaccine doses. Benzinga · Apr 5, 2022
mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha Benzinga · Apr 5, 2022
FDA clears way for millions to get additional COVID-19 boosters WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections. Tribune News Service · Mar 29, 2022
Benzinga · Mar 29, 2022 Here's Why Moderna Shares Are Rising Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.
Benzinga · Mar 29, 2022 FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People The FDA has approved a second round of the Moderna Inc (NASDAQ:
Tribune News Service · Mar 29, 2022 FDA clears way for millions to get additional COVID-19 boosters U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.
Tribune News Service · Mar 29, 2022 FDA clears way for millions to get additional COVID-19 boosters U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.
StockNews.com · Mar 25, 2022 3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…
Benzinga · Mar 24, 2022 Analyzing Moderna Inc's Short Interest Moderna Inc's (NASDAQ:MRNA) short percent of float has risen 7.66% since its last report. The company recently reported that it has 17.61 million shares sold short, which is 5.06% of all regular shares that are available for trading.
Benzinga · Mar 23, 2022 Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6 Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…
Benzinga · Mar 22, 2022 Why Moderna Shares Are Trading Higher Today Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.
Benzinga · Mar 22, 2022 Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…
StockNews.com · Mar 21, 2022 5 Cheap Value Stocks to Add to Your Portfolio Despite the latest federal interest rate hikes, undervalued stocks with impressive financials are expected to deliver solid returns in the coming months. So, we think it could be wise to scoop up quality stocks Moderna (MRNA), Bayer (BAYRY), Henkel (HENKY), AGCO (AGCO), and Penske Automotive (PAG), which are currently trading…
Businessweek · Mar 21, 2022 The Future of Boosters Is Somewhere Between Unnecessary and Urgent Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.